Multivariate Cox model analysis for overall and event-free survival of the 126 childhood acute lymphoblastic leukemia patients
| Variable . | Univariate analysis . | Multivariate analysis . | ||
|---|---|---|---|---|
| P . | P . | RR . | 95% CI . | |
| OS | ||||
| p16INK4aICC* | .0014 | .0204 | 3.38 | 1.20 -9.48 |
| Karyotype† | .0032 | .0227 | 3.92 | 1.21 -12.72 |
| Age‡ | .0165 | .12 | 2.30 | 0.81 -6.61 |
| WBC1-153 | .0425 | .0719 | 2.55 | 0.92 -7.09 |
| Prednisone response day 81-155 | .069 | — | — | — |
| Hemoglobin1-154 | .964 | — | — | — |
| Bulky tumor mass | .27 | — | — | — |
| Immunophenotype1-159 | .25 | — | — | — |
| Sex | .8425 | — | — | — |
| EFS | ||||
| p16INK4aICC* | .0033 | .0188 | 2.49 | 1.16 -5.32 |
| Karyotype† | .0609 | — | — | — |
| Age‡ | .0374 | .0735 | 2.06 | 0.93 -4.55 |
| WBC1-153 | .297 | — | — | — |
| Prednisone response day 81-155 | .4 | — | — | — |
| Hemoglobin1-154 | .73 | — | — | — |
| Bulky tumor mass | .77 | — | — | — |
| Immunophenotype1-159 | .28 | — | — | — |
| Sex | .52 | — | — | — |
| Variable . | Univariate analysis . | Multivariate analysis . | ||
|---|---|---|---|---|
| P . | P . | RR . | 95% CI . | |
| OS | ||||
| p16INK4aICC* | .0014 | .0204 | 3.38 | 1.20 -9.48 |
| Karyotype† | .0032 | .0227 | 3.92 | 1.21 -12.72 |
| Age‡ | .0165 | .12 | 2.30 | 0.81 -6.61 |
| WBC1-153 | .0425 | .0719 | 2.55 | 0.92 -7.09 |
| Prednisone response day 81-155 | .069 | — | — | — |
| Hemoglobin1-154 | .964 | — | — | — |
| Bulky tumor mass | .27 | — | — | — |
| Immunophenotype1-159 | .25 | — | — | — |
| Sex | .8425 | — | — | — |
| EFS | ||||
| p16INK4aICC* | .0033 | .0188 | 2.49 | 1.16 -5.32 |
| Karyotype† | .0609 | — | — | — |
| Age‡ | .0374 | .0735 | 2.06 | 0.93 -4.55 |
| WBC1-153 | .297 | — | — | — |
| Prednisone response day 81-155 | .4 | — | — | — |
| Hemoglobin1-154 | .73 | — | — | — |
| Bulky tumor mass | .77 | — | — | — |
| Immunophenotype1-159 | .28 | — | — | — |
| Sex | .52 | — | — | — |
RR indicates relative risk; CI, confidence interval; OS, event-free survival; ICC, immunocytochemistry; WBC, white blood count; EFS, event-free survival.
Greater than 5% acute lymphoblastic leukemia cells; 5% or fewer acute lymphoblastic leukemia cells.
High risk, including t(9; 22), t(4; 11), t(1; 19) and hypodiploid; intermediate and low risk.
Younger than 1 and older than 9 years; 1 year or older and 9 years or younger.
Lower than 50 000/μL; 50 000/μL or higher.
Circulating blasts at 1000/μL or more; fewer than 1000/μL circulating blasts.
More than 11 g/dL; lower than 11 g/dL.
T-acute lymphoblastic leukemia; B-precursor acute lymphoblastic leukemia.